BI 1831169
AXP000120.1 · Oncolytic virus
- Platform
- VSV-GP (vesicular stomatitis virus with LCMV glycoprotein)
- Originator
- Viratherapeutics
- Sponsor
- Boehringer Ingelheim
Names
Virus
- Role
- Oncolytic
- Family
- Rhabdoviridae
- Virus
- vesicular stomatitis Indiana virus (NCBI Taxonomy 11277)
- Strain
- VSV-GP chimera
- Replication
- replicating
- Modifications
- VSV G protein replaced by lymphocytic choriomeningitis virus glycoprotein (GP)
- Route
- intravenous, intratumoral
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07176975 | A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers | Suspended | Phase 1 | 2027-08-03 | 2028-12-19 | 46 | Solid Tumors |
| NCT05155332 | A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) | Suspended | Phase 1 | 2022-03-28 | 2028-07-18 | 190 | Solid Tumors |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 35699077 | Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors. | Future oncology (London, England) | 2022 | cited by trial NCT05155332 |
Other papers
Preclinical studies, reviews and other papers that name it.
No confirmed other papers yet.
Unconfirmed matches (22)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41766922 | The oncolytic vesicular stomatitis virus VSV-GP shows profound oncolytic activity in NUT-carcinoma cell lines. | Molecular therapy. Oncology | 2026 | name in title: VSV-GP |
| PMID 41893803 | Protein Priming Followed by a Replication-Competent VSV-GP Vector Boost Induces Sustained Immune Control in Therapeutic Hepatitis B Vaccination. | Vaccines | 2026 | name in title: VSV-GP |
| PMID 42191950 | An ex vivo permissivity assay to assess replication of the oncolytic virus VSV-GP in patient-derived tumor samples. | Oncogene | 2026 | name in title: VSV-GP |
| PMID 40013517 | Molecular Pathology Methods to Characterize Biodistribution and Pharmacodynamics of the Oncolytic Virus VSV-GP in a Nonclinical Tumor Model. | Toxicologic pathology | 2025 | name in title: VSV-GP |
| PMID 40083959 | Characterization of VSV-GP morphology by cryo-EM imaging and SEC-MALS. | Molecular therapy. Methods & clinical development | 2025 | name in title: VSV-GP |
| PMID 40521092 | Perfusion process with tangential flow filtration for oncolytic VSV-GP production. | Frontiers in bioengineering and biotechnology | 2025 | name in title: VSV-GP |
| PMID 40835316 | Interleukin-12 encoded by the oncolytic virus VSV-GP enhances therapeutic antitumor efficacy by inducing CD8+ T-cell responses with a long-lived effector cell phenotype. | Journal for immunotherapy of cancer | 2025 | name in title: VSV-GP |
| PMID 41282468 | Newly identified oncolytic VSV-GP-specific CD8+ T cell epitopes for monitoring of anti-viral immune responses in the BALB/c mouse model. | Molecular therapy. Oncology | 2025 | name in title: VSV-GP |
| PMID 41398167 | Heterologous combinations of VSV-GP and native-like trimers elicit autologous Tier 2 HIV antibodies in rabbits. | NPJ vaccines | 2025 | name in title: VSV-GP |
| PMID 38916347 | Absolute quantification of viral proteins from pseudotyped VSV-GP using UPLC-MRM. | Microbiology spectrum | 2024 | name in title: VSV-GP |
| PMID 39203993 | Characterization of the Anti-Viral and Vaccine-Specific CD8+ T Cell Composition upon Treatment with the Cancer Vaccine VSV-GP. | Vaccines | 2024 | name in title: VSV-GP |
| PMID 39703791 | Repeated harvest enables efficient production of VSV-GP. | Frontiers in bioengineering and biotechnology | 2024 | name in title: VSV-GP |
| PMID 36700123 | Nonclinical pharmacokinetics and biodistribution of VSV-GP using methods to decouple input drug disposition and viral replication. | Molecular therapy. Methods & clinical development | 2023 | name in title: VSV-GP |
| PMID 37086948 | Therapeutic Efficacy of a VSV-GP-based Human Papilloma Virus Vaccine in a Murine Cancer Model. | Journal of molecular biology | 2023 | name in title: VSV-GP |
| PMID 36394051 | Single-step rapid chromatographic purification and characterization of clinical stage oncolytic VSV-GP. | Frontiers in bioengineering and biotechnology | 2022 | name in title: VSV-GP |
| PMID 36741416 | Prediction and validation of murine MHC class I epitopes of the recombinant virus VSV-GP. | Frontiers in immunology | 2022 | name in title: VSV-GP |
| PMID 31530903 | The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer. | British journal of cancer | 2019 | name in title: VSV-GP |
| PMID 31921191 | Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses. | Frontiers in immunology | 2019 | name in title: VSV-GP |
| PMID 29498639 | The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma. | Viruses | 2018 | name in title: VSV-GP |
| PMID 29696636 | Oncolytic activity of the rhabdovirus VSV-GP against prostate cancer. | International journal of cancer | 2018 | name in title: VSV-GP |
| PMID 27738655 | Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy. | Molecular therapy oncolytics | 2016 | name in title: VSV-GP |
| PMID 24554655 | VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications. | Journal of virology | 2014 | name in title: VSV-GP |
Notes
Chimeric VSV whose G protein is replaced by the LCMV glycoprotein (VSV-GP), reducing neurotoxicity. Viratherapeutics was acquired by Boehringer Ingelheim in 2018. Given both intravenously and intratumorally in study 1456-0001.
How to cite
BI 1831169 (AXP000120.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000120.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.